Bigul

Zydus Cadila receives USFDA's final approval to market sedative injection

The injection will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad
28-02-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Zydus receives final approval from the USFDA for Dexmedetomidine Hydrochloride Injection
28-02-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

'Cadila Healthcare's Moraiya facility successfully completes USFDA inspection.'
09-02-2018
Bigul

Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share

Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these
09-02-2018
Bigul

Press Release On The Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2017.

Press Release on the unaudited financial results for the quarter / nine months ended on December 31, 2017.
08-02-2018
Bigul

Financial Results For The Quarter / Nine Months Ended 31/12/2017.

Financial Results for the quarter / nine months ended 31/12/2017.
08-02-2018
Bigul

Updates

Clarification w.r.t. news item which appeared in the Bloombergquint.
07-02-2018
Bigul

Clarification sought from Cadila Healthcare Ltd

The Exchange has sought clarification from Cadila Healthcare Ltd on February 07, 2018, with reference to news appeared in www.bloombergquint.com dated February 07, 2018 quoting "U.S. FDA Conducts Surprise Audit At Cadila's Moraiya Plant". The reply is awaited.
07-02-2018
Bigul

Analyst / Investor Meet - Intimation

Pursuant to regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a conference call on February 8, 2018 at 4:00 p.m., post announcement of unaudited financial results for the quarter / nine months ended on December 31, 2017.
31-01-2018
Bigul

Cadila Healthcare turns focus on vaccines and biosimilars

Analysts expect the two segments to contribute 25% of domestic revenue in 2 years; vaccines contribute less than 1% of revenues at present, while biosimilars account for 4.5% of domestic revenues
24-01-2018
Next Page
Close

Let's Open Free Demat Account